Biovica announces two new customers and sales of 1,5 MSEK
Uppsala, the 19th of March 2019. Two new customers have purchased DiviTum®-kits in order to evaluate response to treatment in breast cancer studies. The customers are pharma- and CRO-companies (Contract Research Organization) based in US and Europe.
“We are glad to see that there is a demand for DiviTum® on the research market and an interest to include it in clinical trials in order to effectively follow up cancer treatments. We’re pleased that pharma companies see the value of our product and use it in clinical trials in order to provide better treatments for the patients.”, says Anders Rylander, CEO Biovica.
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB, firstname.lastname@example.org, +46 8 528 00 399.
Read more: www.biovica.com